
Venus Concept VERO
$ 1.76
-1.12%
Quarterly report 2025-Q3
added 11-13-2025
Venus Concept Book Value 2011-2025 | VERO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.84 M | -13.4 M | 8.74 M | 41.6 M | 43.8 M | 74.2 M | 1.58 M | 13.2 M | -144 M | -122 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.2 M | -144 M | -9.33 M |
Quarterly Book Value Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.13 M | 2.77 M | 2.73 M | 2.84 M | 10.6 M | 4.36 M | -21.9 M | -13.4 M | -11.4 M | -5.54 M | -207 K | 8.74 M | 10 M | 23.4 M | 33.4 M | 41.6 M | 28.8 M | 36.8 M | 35.9 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 76.7 M | 76.7 M | 76.7 M | 76.7 M | 36.5 M | 1.58 M | 1.58 M | 1.58 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | -7.81 M | -7.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 76.7 M | -21.9 M | 20.3 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
1.33 B | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.6 | - | $ 125 M | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 96.13 | 0.04 % | $ 141 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 301.75 | 0.24 % | $ 8.51 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 48.12 | 0.21 % | $ 7.17 K | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 124.81 | 0.22 % | $ 217 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 2.97 | 4.58 % | $ 111 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 14.47 | 0.7 % | $ 1.15 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 9.54 | - | $ 685 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
3.85 B | $ 157.84 | 0.69 % | $ 11.8 B | ||
|
NanoVibronix
NAOV
|
627 K | - | - | $ 1.08 M | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 0.86 | 0.43 % | $ 88.4 M | ||
|
Myomo
MYO
|
6.36 M | $ 1.02 | 12.09 % | $ 7.19 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 14.49 | 0.84 % | $ 392 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 14.53 | 0.07 % | $ 95.2 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.14 | 3.64 % | $ 18.4 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 97.06 | 0.48 % | $ 1.23 B | ||
|
AxoGen
AXGN
|
104 M | $ 32.64 | -0.61 % | $ 1.44 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
963 M | $ 40.17 | 1.34 % | $ 1.24 B | ||
|
OrthoPediatrics Corp.
KIDS
|
355 M | $ 17.41 | 0.75 % | $ 402 M | ||
|
Globus Medical
GMED
|
4.18 B | $ 88.43 | -0.38 % | $ 12 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 12.66 | 0.56 % | $ 975 M | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 63.08 | -0.27 % | $ 3.42 B | ||
|
Aethlon Medical
AEMD
|
5.12 M | $ 2.49 | -6.39 % | $ 3.89 M | ||
|
LENSAR
LNSR
|
18.6 M | $ 12.01 | -0.08 % | $ 138 M |